Kita Takeshi, Clermont Allen C, Murugesan Nivetha, Zhou Qunfang, Fujisawa Kimihiko, Ishibashi Tatsuro, Aiello Lloyd Paul, Feener Edward P
Joslin Diabetes Center, Harvard Medical School, Boston, MA.
Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka City, Japan.
Diabetes. 2015 Oct;64(10):3588-99. doi: 10.2337/db15-0317. Epub 2015 May 15.
This study characterizes the kallikrein-kinin system in vitreous from individuals with diabetic macular edema (DME) and examines mechanisms contributing to retinal thickening and retinal vascular permeability (RVP). Plasma prekallikrein (PPK) and plasma kallikrein (PKal) were increased twofold and 11.0-fold (both P < 0.0001), respectively, in vitreous from subjects with DME compared with those with a macular hole (MH). While the vascular endothelial growth factor (VEGF) level was also increased in DME vitreous, PKal and VEGF concentrations do not correlate (r = 0.266, P = 0.112). Using mass spectrometry-based proteomics, we identified 167 vitreous proteins, including 30 that were increased in DME (fourfold or more, P < 0.001 vs. MH). The majority of proteins associated with DME displayed a higher correlation with PPK than with VEGF concentrations. DME vitreous containing relatively high levels of PKal and low VEGF induced RVP when injected into the vitreous of diabetic rats, a response blocked by bradykinin receptor antagonism but not by bevacizumab. Bradykinin-induced retinal thickening in mice was not affected by blockade of VEGF receptor 2. Diabetes-induced RVP was decreased by up to 78% (P < 0.001) in Klkb1 (PPK)-deficient mice compared with wild-type controls. B2- and B1 receptor-induced RVP in diabetic mice was blocked by endothelial nitric oxide synthase (NOS) and inducible NOS deficiency, respectively. These findings implicate the PKal pathway as a VEGF-independent mediator of DME.
本研究对糖尿病性黄斑水肿(DME)患者玻璃体中的激肽释放酶-激肽系统进行了特征分析,并探讨了导致视网膜增厚和视网膜血管通透性(RVP)增加的机制。与黄斑裂孔(MH)患者相比,DME患者玻璃体中的血浆前激肽释放酶(PPK)和血浆激肽释放酶(PKal)分别升高了2倍和11.0倍(均P < 0.0001)。虽然DME玻璃体中的血管内皮生长因子(VEGF)水平也有所升高,但PKal和VEGF浓度之间无相关性(r = 0.266,P = 0.112)。利用基于质谱的蛋白质组学技术,我们鉴定出167种玻璃体蛋白,其中30种在DME中升高(是MH的4倍或更高,P < 0.001)。与DME相关的大多数蛋白质与PPK的相关性高于与VEGF浓度的相关性。将含有相对高水平PKal和低水平VEGF的DME玻璃体注射到糖尿病大鼠玻璃体中可诱导RVP,缓激肽受体拮抗剂可阻断该反应,但贝伐单抗不能。缓激肽诱导的小鼠视网膜增厚不受血管内皮生长因子受体2阻断的影响。与野生型对照相比,Klkb1(PPK)缺陷小鼠中糖尿病诱导的RVP降低了78%(P < 0.001)。糖尿病小鼠中B2和B1受体诱导的RVP分别被内皮型一氧化氮合酶(NOS)和诱导型NOS缺陷所阻断。这些发现表明PKal途径是DME中不依赖VEGF的介质。